Ghent University Academic Bibliography

Advanced

EGFR in melanoma: clinical significance and potential therapeutic target

Barbara Boone UGent, Koen Jacobs, LIESBETH FERDINANDE UGent, Jasmien Taildeman UGent, Jo Lambert UGent, Marc Peeters UGent, Marc Bracke UGent, Patrick Pauwels UGent and Lieve Brochez UGent (2011) JOURNAL OF CUTANEOUS PATHOLOGY. 38(6). p.492-502
abstract
Background: The role of epidermal growth factor receptor (EGFR) has been established in a range of neoplasms. In melanoma, data on EGFR protein expression are conflicting. Fluorescence in situ hybridization ( FISH) analysis for EGFR gene expression in melanoma showed EGFR gene amplification to be linked with worse prognosis. Cetuximab has been shown to suppress the formation of metastasis in Methods: EGFR protein expression and gene copy number status were evaluated by means of immunohistochemistry and FISH in melanoma samples of patients with known clinicopathological data. Associations between EGFR expression and prognostic parameters were investigated. The effect of different cetuximab concentrations on the BLM melanoma cell line was evaluated by means of methyl tetrazolium (MTT), sulforhodamine B (SRB) and Matrigel invasion assays. Results: EGFR protein expression was more frequently observed in patients with a positive sentinel lymph node. However, EGFR immunostaining has no predictive value. The presence of EGFR polysomy was associated with thicker tumors. Treatment of the BLM melanoma cell line with different concentrations of cetuximab reduced the invasive capacity of the cells, but did not alter cell viability or growth. Conclusion: EGFR appears to be involved in progression and metastasis of a subset of melanomas. Targeting EGFR could therefore represent a therapeutic option for these melanomas.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
cancer research, dermatopathology, malignant melanoma, GROWTH-FACTOR RECEPTOR, CELL LUNG-CANCER, METASTATIC MELANOMA, MALIGNANT MELANOMAS, CUTANEOUS MELANOMA, POOR-PROGNOSIS, EXPRESSION, GENE, MELANOCYTES, PROGRESSION
journal title
JOURNAL OF CUTANEOUS PATHOLOGY
J. Cutan. Pathol.
volume
38
issue
6
pages
492 - 502
Web of Science type
Article
Web of Science id
000289949500007
JCR category
DERMATOLOGY
JCR impact factor
1.561 (2011)
JCR rank
28/58 (2011)
JCR quartile
2 (2011)
ISSN
0303-6987
DOI
10.1111/j.1600-0560.2011.01673.x
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
1210949
handle
http://hdl.handle.net/1854/LU-1210949
date created
2011-04-20 13:57:04
date last changed
2012-04-26 10:49:14
@article{1210949,
  abstract     = {Background: The role of epidermal growth factor receptor (EGFR) has been established in a range of neoplasms. In melanoma, data on EGFR protein expression are conflicting. Fluorescence in situ hybridization ( FISH) analysis for EGFR gene expression in melanoma showed EGFR gene amplification to be linked with worse prognosis. Cetuximab has been shown to suppress the formation of metastasis in 
Methods: EGFR protein expression and gene copy number status were evaluated by means of immunohistochemistry and FISH in melanoma samples of patients with known clinicopathological data. Associations between EGFR expression and prognostic parameters were investigated. The effect of different cetuximab concentrations on the BLM melanoma cell line was evaluated by means of methyl tetrazolium (MTT), sulforhodamine B (SRB) and Matrigel invasion assays. 
Results: EGFR protein expression was more frequently observed in patients with a positive sentinel lymph node. However, EGFR immunostaining has no predictive value. The presence of EGFR polysomy was associated with thicker tumors. Treatment of the BLM melanoma cell line with different concentrations of cetuximab reduced the invasive capacity of the cells, but did not alter cell viability or growth. 
Conclusion: EGFR appears to be involved in progression and metastasis of a subset of melanomas. Targeting EGFR could therefore represent a therapeutic option for these melanomas.},
  author       = {Boone, Barbara and Jacobs, Koen and FERDINANDE, LIESBETH and Taildeman, Jasmien and Lambert, Jo and Peeters, Marc and Bracke, Marc and Pauwels, Patrick and Brochez, Lieve},
  issn         = {0303-6987},
  journal      = {JOURNAL OF CUTANEOUS PATHOLOGY},
  keyword      = {cancer research,dermatopathology,malignant melanoma,GROWTH-FACTOR RECEPTOR,CELL LUNG-CANCER,METASTATIC MELANOMA,MALIGNANT MELANOMAS,CUTANEOUS MELANOMA,POOR-PROGNOSIS,EXPRESSION,GENE,MELANOCYTES,PROGRESSION},
  language     = {eng},
  number       = {6},
  pages        = {492--502},
  title        = {EGFR in melanoma: clinical significance and potential therapeutic target},
  url          = {http://dx.doi.org/10.1111/j.1600-0560.2011.01673.x},
  volume       = {38},
  year         = {2011},
}

Chicago
Boone, Barbara, Koen Jacobs, Liesbeth Ferdinande, Jasmien Taildeman, Jo Lambert, Marc Peeters, Marc Bracke, Patrick Pauwels, and Lieve Brochez. 2011. “EGFR in Melanoma: Clinical Significance and Potential Therapeutic Target.” Journal of Cutaneous Pathology 38 (6): 492–502.
APA
Boone, Barbara, Jacobs, K., Ferdinande, L., Taildeman, J., Lambert, J., Peeters, M., Bracke, M., et al. (2011). EGFR in melanoma: clinical significance and potential therapeutic target. JOURNAL OF CUTANEOUS PATHOLOGY, 38(6), 492–502.
Vancouver
1.
Boone B, Jacobs K, Ferdinande L, Taildeman J, Lambert J, Peeters M, et al. EGFR in melanoma: clinical significance and potential therapeutic target. JOURNAL OF CUTANEOUS PATHOLOGY. 2011;38(6):492–502.
MLA
Boone, Barbara, Koen Jacobs, Liesbeth Ferdinande, et al. “EGFR in Melanoma: Clinical Significance and Potential Therapeutic Target.” JOURNAL OF CUTANEOUS PATHOLOGY 38.6 (2011): 492–502. Print.